Israel - heprea - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - hydrocortisone as sodium succinate - אבקה להמסה להזרקה\אינפוזיה - hydrocortisone as sodium succinate 100 mg - hydrocortisone - hydrocortisone - glucocorticosteroid, anti-inflammatory and anti-allergic .

Israel - heprea - Ministry of Health

ה.א. שיטות יבוא דנטלי בע"מ - רופא שיניים - gbr, orthodontics

Israel - heprea - Ministry of Health

teva pharmaceutical indust.ltd - valaciclovir hydrochloride (as dihydrate) 500 mg - film coated tablets - valaciclovir - valaciclovir teva is indicated for the treatment of herpes zoster (shingles) in immunocompetent adults . valaciclovir teva accelerates the resolution of pain, it reduces the duration, and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia. the efficacy of valaciclovir teva in immunocompromised patients has not been established. - valaciclovir teva is indicated for the treatment of the initial and recurrent genital herpes due to herpes simplex infection. - valaciclovir is indicated for the prevention (suppression) of recurrent herpes simplex infections (herpes genitalis). - prophylaxis of cytomegalovirus infection and disease, following organ transplantation. - for the treatment of cold sores (herpes labialis).

Israel - heprea - Ministry of Health

rafa laboratories ltd - valaciclovir as hydrochloride 500 mg - film coated tablets - valaciclovir - valovir is indicated for the treatment of herpes zoster (shingles) in immunocopotent adults. valovir accelerates the resolution of pain, it reduces the duration, and the proportion of patients with zoster-associated pain, which includes acute and post-herpetic neuralgia. the efficacy of valaciclovir in immunocompromised patients has not been established.valovir is indicated for the treatment of the initial and recurrent genital herpes due to herpes simplex infection. valovir is indicated for the prevention (suppression) of recurrent herpes simplex infections (herpes genitalis). prophylaxis of cytomegalovirus infection and disease, following organ transplantation. for the treatment of cold sores (herpes labialis).

Israel - heprea - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - תרחיף - aciclovir 200 mg / 5 ml - aciclovir - aciclovir - zovirax oral presentations are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes, for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients, for the prophylaxis of herpes simplex infections in immune-compromised patients and for the treatment of herpes zoster (shingles) infections. studies have shown that early treatment of shingles with zovirax has a beneficial effect on pain and can reduce the incidence of post-herpetic neuralgia (zoster associated pain). zovirax oral presentations should be considered for the treatment of chickenpox in certain groups at increased risk of severe varicella or its complications. these groups are as follows: 1. non-pregnant patients over 13 years-of-age who are otherwise healthy. 2. children over 12 months of age with a chronic cutaneous or pulmonary condition, or receiving long-term salicylate therapy. 3. children receiving sho

Israel - heprea - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 5 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Israel - heprea - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 15 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Israel - heprea - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 20 mg - ruxolitinib - ruxolitinib - jakavi is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.

Israel - heprea - Ministry of Health

novartis israel ltd - ruxolitinib as phosphate - טבליה - ruxolitinib as phosphate 10 mg - ruxolitinib

Israel - heprea - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - טבליות ניתנות לפיזור - aciclovir 800 mg - aciclovir - aciclovir - for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes. for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients. for the prophylaxis of herpes simplex infections in immune-compromised patients. for the treatment of herpes zoster infections . for the treatment of chickenpox in the following groups: 1. non-pregnant patients over 13 years-of-age who are otherwise healthy. 2. children over 12 months of age with a chronic cutaneous or pulmonary condition, or receiving long-term salicylate therapy. 3. children receiving short or intermittent courses of aerosolized corticosteroids.